Fig. 1
From: European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis
DOOR grades disease-related health status from the worst state (rank 0) to the best one (rank 4) based on the number and severity of the reported events (e.g., vascular events) occurring during the observational time frame or the conditions reported at the end of the time frame (e.g., transfusion-dependent anemia).
